Hepatorenal Syndrome (HRS) — Management

Pathophysiology

Proposed pathophysiology of HRS — Sleisenger & Fordtran's, Fig. 94.2

1. Splanchnic arterial vasodilation (mediated by NO, CO, glucagon, prostacyclin, adrenomedullin) — the primary driver
2. Compensatory renal vasoconstriction via RAAS, SNS, and ADH activation
3. Cardiac dysfunction (cirrhotic cardiomyopathy further reduces effective output)

Classification (Updated Terminology)

Diagnostic Criteria (ICA 2015 Revised)

1. Cirrhosis with ascites
2. AKI by ICA criteria (creatinine rise ≥0.3 mg/dL in 48 h OR ≥50% from baseline)
3. No response after ≥48 hours of diuretic withdrawal + IV albumin 1 g/kg/day (max 100 g/day)
4. Absence of shock
5. No current/recent nephrotoxic drugs
6. No parenchymal renal disease (proteinuria <500 mg/day, no microhematuria >50 RBC/hpf, normal renal ultrasound)

Key point: Urine output criteria are NOT used in cirrhotic patients because they are frequently oliguric at baseline due to sodium retention.

Management

Step 1 — Identify and Remove Precipitants

• SBP/sepsis (present in ~30% preceding HRS; treat with antibiotics ± albumin)
• Volume depletion — overdiuresis, GI hemorrhage, diarrhea (lactulose overdose)
• Nephrotoxins — NSAIDs, aminoglycosides, contrast agents
• Vasodilators — ACEIs, ARBs

Step 2 — Volume Expansion with Albumin

• IV albumin 1 g/kg/day (max 100 g/day) for 48 hours
• Serves both as a volume expander and to bind circulating vasoactive mediators
• Lack of response after 48 h is required to confirm HRS diagnosis

Step 3 — Vasoconstrictors (First-Line Treatment)

🥇 Terlipressin + Albumin (First-Line, where available)

• Selective vasopressin V1 receptor agonist; IV bolus or continuous infusion
• Continuous infusion is better tolerated and effective at lower doses than bolus dosing
• Two pivotal RCTs (OT-0401 and REVERSE trials): terlipressin + albumin reversed HRS in 27% vs. 14% with albumin alone (P = 0.004)
• Creatinine improvement: 30–43% vs. 8–13% with albumin alone
• Response is better with lower baseline creatinine and lower bilirubin — supports early initiation
• Dosing (Box 94.3): bolus 0.5–2 mg IV q4–6h; or infusion 2–12 mg/day
• Adverse effects: cardiovascular complications (ischemia, arrhythmia) — close monitoring required; respiratory failure in ACLF patients

🥈 Norepinephrine + Albumin (Alternative, ICU setting)

• IV α1-agonist; requires ICU monitoring
• Two small RCTs: equal efficacy and safety to terlipressin
• Response rates 40–75%; relapse ~20%
• Significant cardiovascular side effects reported
• Preferred in ICU when terlipressin is unavailable

🥉 Midodrine + Octreotide + Albumin (Third-Line, USA)

• Midodrine: oral α1-agonist (titrated to ↑MAP); Octreotide: somatostatin analog (inhibits endogenous vasodilators)
• Easier to administer (oral midodrine); favorable safety profile
• Head-to-head RCT vs. terlipressin: renal recovery 28.6% vs. 70.4% (P = 0.01) — significantly inferior to terlipressin
• Used most commonly in the US where terlipressin availability has been limited, but now classified as third-line
• Dosing: Midodrine 7.5–15 mg PO TID; Octreotide 100–200 mcg SC TID; Albumin 20–40 g/day IV

Step 4 — Renal Replacement Therapy

• Initiated when pharmacologic therapy fails
• Bridge to liver transplantation, not a definitive treatment
• Does not improve underlying pathophysiology

Step 5 — TIPS (Transjugular Intrahepatic Portosystemic Shunt)

• Reduces portal hypertension, improving splanchnic hemodynamics
• Limited data in HRS specifically; more evidence in refractory ascites
• Contraindicated in advanced hepatic encephalopathy, severe hepatic insufficiency (bilirubin >5 mg/dL), MELD >18 in most protocols

Step 6 — Liver Transplantation (Definitive Therapy)

• Best and only curative treatment for HRS
• Recovery of renal function is typical post-transplant in HRS (kidneys are histologically normal)
• Pre-transplant treatment with vasoconstrictors may improve candidacy and bridge to transplant
• For HRS-CKD: simultaneous liver-kidney transplantation (SLKT) may be considered
• In both HRS-AKI and HRS-CKD, prognosis is poor without transplant

Prevention

Prognosis

• HRS-AKI (Type 1): median survival without treatment is 2–4 weeks; with terlipressin bridge to transplant, outcomes improve substantially
• HRS-CKD (Type 2): median survival ~6 months
• HRS reversal with vasoconstrictors does not significantly improve overall survival unless transplantation is achieved

Recent Evidence